HCV-NS4B is an ER-localized 27-kDa protein with several functions in the HCV life cycle. Cellular expression

of NS4B induces convolution of the ER membrane and formation of a membranous web that harbors HCV replicase complex.44, 45 NS4B also has RNA-binding capacity.46 In addition, several point mutations of NS4B were found to alter viral replication activity.33, 46, 47 The studies above indicate that NS4B provides an important protein-protein or protein-RNA interaction platform within the HCV replication complex and is essential for viral RNA replication. However, there are few reports on the involvement of NS4B with antiviral immune responses. Consistent with our previous study, Moriyama et al.48 reported that NS4B partially inhibited dsRNA-induced but not TRIF-induced activation of IFN-β. In NS4B-expressing XL765 concentration cells, IFN-α induced activation of STAT1 was suppressed.49 The present study has demonstrated that NS4B functions against the host IFN response, such that NS4B directly interacts with STING and suppresses downstream signaling, resulting in the induction of IFN production. STING contains a domain homologous to the N terminus of NS4B derived from several flaviviruses, including HCV. In our previous NS4B truncation assay, the NS4B N-terminal domain (amino

acids 1-110) was important for suppression of RIG-I–induced IFN-β Roxadustat molecular weight expression.19 Consistent with these results, N-terminally truncated NS4B (NS4Bt1-84) significantly suppressed STING and Cardif-induced IFN-β promoter activation, whereas the C terminus of NS4B (NS4Bt85-261) did not (Fig. 7). These results reinforce

our hypothesis that NS4B binds STING at its homology domain and blocks the ability of STING to induce IFN-β production. A small molecule inhibitor of NS4B has been developed and is under preliminary clinical trials.50 Einav et al.51 identified MCE公司 clemizole hydrochloride, an H1 histamine receptor antagonist, as an inhibitor of the RNA-binding function of NS4B and HCV RNA replication. A phase 1B clinical trial of clemizole in hepatitis C patients has been completed.52 Other two NS4B inhibitors which are a compound of amiloride analog and anguizole are under preclinical development.53, 54 The possibility remains that such NS4B inhibitors may suppress HCV replication partly through inhibiting the ability of NS4B to suppress IFN-β production and restore cellular antiviral responses. In conclusion, IFN production signaling induced by HCV infection and mediated by RIG-I is suppressed by NS4B through a direct interaction with STING. These virus-host interactions help to elucidate the mechanisms of persistent HCV infection and constitute a potential target to block HCV infection. The authors are indebted to J. Tcshopp for providing Cardif, ΔCARD, and CARD and to G. N. Barber for the STING plasmids.